Trial design
MAY
This was a 10-week randomized placebo-controlled trial with a parallel design. Participants were recruited from Baqiyatallah hospital through a convenience sampling method between November 2021 and May 2022, and were randomized to the synbiotic (n = 28) or the placebo (n = 28) group. Prior to the start of the trial, the Medical Ethics Committee of Baqiyatallah University of Medical Sciences approved the study (IR.BMSU.BAQ.REC.1400.021; available at: 